Remibrutinib versus teriflunomide in relapsing multiple sclerosis (REMODEL-1 and REMODEL-2): two randomised, phase 3 trials.

Wiendl H, Bermel R, Airas L, Chitnis T, Nakahara J, Williams M, Adamczyk-Sowa M, Piasecka-Stryczynska K, Zielman R, Dunphy S, Panchaud N, Cai M, Xi J, Loop B, Su W, Willi R, Montalban X, REMODEL Investigators

Open source

DOI: 10.1016/s0140-6736(26)02058-1
Published: 2026 Oct 23
Container: Lancet (London, England)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-26-02058-1,
  title = {Remibrutinib versus teriflunomide in relapsing multiple sclerosis (REMODEL-1 and REMODEL-2): two randomised, phase 3 trials.},
  author = {Wiendl H and Bermel R and Airas L and Chitnis T and Nakahara J and Williams M and Adamczyk-Sowa M and Piasecka-Stryczynska K and Zielman R and Dunphy S and Panchaud N and Cai M and Xi J and Loop B and Su W and Willi R and Montalban X and REMODEL Investigators},
  year = {2026},
  journal = {Lancet (London, England)},
  doi = {10.1016/s0140-6736(26)02058-1},
  url = {https://doi.org/10.1016/s0140-6736(26)02058-1}
}

RIS

TY  - JOUR
TI  - Remibrutinib versus teriflunomide in relapsing multiple sclerosis (REMODEL-1 and REMODEL-2): two randomised, phase 3 trials.
AU  - Wiendl H
AU  - Bermel R
AU  - Airas L
AU  - Chitnis T
AU  - Nakahara J
AU  - Williams M
AU  - Adamczyk-Sowa M
AU  - Piasecka-Stryczynska K
AU  - Zielman R
AU  - Dunphy S
AU  - Panchaud N
AU  - Cai M
AU  - Xi J
AU  - Loop B
AU  - Su W
AU  - Willi R
AU  - Montalban X
AU  - REMODEL Investigators
PY  - 2026
JO  - Lancet (London, England)
DO  - 10.1016/s0140-6736(26)02058-1
UR  - https://doi.org/10.1016/s0140-6736(26)02058-1
ER  -

APA

H, W., R, B., L, A., T, C., J, N., M, W., M, A., K, P., R, Z., S, D., N, P., M, C., J, X., B, L., W, S., R, W., X, M., & Investigators, R. (2026). Remibrutinib versus teriflunomide in relapsing multiple sclerosis (REMODEL-1 and REMODEL-2): two randomised, phase 3 trials.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(26)02058-1

Source records

pubmed · retrieved 2026-11-11T00:30:54.463Z